Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration

Active, not recruitingOBSERVATIONAL
Enrollment

833

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

March 9, 2025

Study Completion Date

September 30, 2025

Conditions
Neovascular Age-Related Macular Degeneration (nAMD)Treatment-naïve
Interventions
DRUG

Faricimab Injection [Vabysmo]

The procedures were carried out according to the local standard protocol, which involved applying 2-3 drops of topical tetracaine anesthesia, using an eye speculum, disinfecting with 5% povidone-iodine, employing a 33G needle, marking the injection site 3.5 mm posterior to the limbus with calipers in either the superotemporal or inferotemporal quadrant, applying a sterile cotton tip for tamponade after needle removal, and omitting post-procedure antibiotics.

Trial Locations (1)

2600

Department of Ophthalmology, Rigshospitalet, Glostrup Municipality

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT06890026 - Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter